More than 90% of our patients accomplish profound symptom relief. We accomplish this with preparation and individualized treatment planning. Our 1 hour holistic intake is used to prepare every patient for their healing experience and develop a personalized treatment plan that includes natural therapies and supplements. We find this preparation allows us to use fewer Ketamine infusions and have a longer lasting effect.

Ketamine infusions for mental health are about 60 minutes and the total appointment is 2 hours to allow for time to check-in with your doctor before and after the infusion. Ketamine infusions for chronic pain can take 2-5 hours, depending on the treatment protocol.

Every patient is different. Clarus Health's holistic program provides most patients more than 4-6 months of symptom relief. This is made possible by addressing the root causes of depression, anxiety, PTSD, and addiction.

Some patients will benefit from Ketamine boosters. There is no one-size-fits-all approach. We individualize therapies to last as long as possible for each patient. Some patients benefit from "booster" sessions 3-6 times a year after completing their initial treatment. You can read Dr. Kaveh's article on Ketamine boosters here.

No. Every patient has a "healing zone," and most patients prefer times of solitude during infusions, which our doctors accommodate when safe and appropriate. You are always safe with your doctor during treatment.

We provide discounts for military, education (teachers and students), first responder, and medical personnel. We recognize the incredible healing potential of these therapies and partner with Advance Care to provide interest-free medical financing. Our services are also HSA-eligible and follow a sliding-scale.

Insurance does not yet cover the latest Ketamine, NAD, and SGB therapy techniques. Clarus Health provides patients a superbill to assist in obtaining reimbursement from your insurance. Contact us to find which codes apply to you.

While ketamine has been FDA approved for over 50 years, ketamine infusions for mental health conditions are still classified as “off-label” and are not currently covered by insurance. However, off-label prescribing is common, accounting for up to 38% of prescriptions. Despite being off-label, IV Ketamine remains one of the safest, fastest-acting, and effective therapies for many mental health conditions.

Because Spravato is FDA-approved, most major insurance plans cover it - including Medicare, Medi-Cal, and commercial insurers - for patients who meet the criteria for treatment-resistant depression or major depressive disorder with suicidal ideation. At our San Francisco clinic we accept Aetna, United Healthcare, Cigna, Medicare, Anthem Blue Cross Blue Shield, and Blue Cross Blue Shield of California for Spravato.

Every plan requires prior authorization, which generally takes anywhere from a few days to a few weeks. We verify your benefits and handle that paperwork before your first session, so you receive a clear out-of-pocket estimate before committing to treatment. This is the main practical advantage of Spravato over IV ketamine, which is used off-label and rarely covered.

Spravato is approved for adults with treatment-resistant depression, generally meaning depression that has not responded adequately to at least two antidepressants, and for adults with major depressive disorder with suicidal ideation. As of 2025 it is also the first and only monotherapy approved for treatment-resistant depression, so eligible patients no longer need a daily oral antidepressant alongside it. Most insurers require documentation of those earlier medication trials as part of prior authorization.

It is not appropriate for everyone. Patients with uncontrolled high blood pressure, aneurysmal vascular disease, a history of psychosis, or active substance use disorder are generally not candidates. Our San Francisco intake evaluation, conducted by our physician team, identifies any contraindications before treatment begins.

Most patients experience a temporary dissociative state — a sense of floating, detachment from surroundings, altered perception of time, or dreamlike thinking. It usually begins within minutes and fades well within the two-hour monitoring window you spend in a private room at our San Francisco office.

You will not be able to drive afterward and should arrange a ride home. Many patients use the hours following a session for quiet reflection or journaling, which our integration therapy team can guide.

Not quite. Spravato is esketamine, one half of the ketamine molecule, delivered as a nasal spray. The ketamine used in IV infusions is the full compound. Both act on NMDA receptors and trigger neuroplasticity.

The practical differences matter more than the chemistry. Spravato is FDA-approved and usually insurance-covered, but its approval is limited to depression. IV ketamine is used off-label and rarely covered, but it can address anxiety, PTSD, chronic pain, and addiction, with faster onset and higher bioavailability. Our San Francisco clinic offers both and recommends based on your diagnosis, coverage, and goals — we cover the tradeoffs in detail in our guide to IV versus nasal ketamine.

In a head-to-head trial against one of the most common alternatives for treatment-resistant depression, Spravato produced significantly higher remission rates at eight weeks, with benefits sustained through 32 weeks.

That said, the best option depends on your full clinical picture. At our San Francisco clinic we also offer stellate ganglion block, genomic testing to guide medication selection, and hormone optimization, since untreated hormonal or metabolic issues frequently sustain depression that looks purely psychiatric.

Treatment follows a tapering schedule rather than a fixed number. The induction phase is twice weekly for roughly the first four weeks, then once weekly, then every one to two weeks for maintenance as your response stabilizes.

Staying on maintenance matters: patients who reach remission and continue treatment see a substantially lower risk of relapse than those who stop. Your San Francisco provider reassesses at every visit and adjusts your protocol accordingly.

The most common are dissociation, dizziness, nausea, temporarily elevated blood pressure, sedation, and headache. Nearly all resolve within the two-hour monitoring period, and your clinical provider manages them in real time.

Spravato carries a boxed warning for sedation, dissociation, and abuse potential, which is precisely why it must be administered in a certified clinic under supervision rather than taken at home. Across nearly six years of real-world use, its safety profile has remained consistent with what clinical trials predicted.

Spravato is a Schedule III controlled substance and carries a boxed warning for abuse and misuse, so the concern is a fair one. The risk is managed structurally rather than left to chance.

The medication is never dispensed for you to take home. You self-administer it in the clinic under direct supervision and are monitored for two hours afterward. These requirements exist under the FDA's REMS program specifically to prevent misuse, and every session at our San Francisco clinic is supervised by a licensed clinical provider.

Hormones all act like a family, meaning your reproductive hormones, thyroid, and adrenal hormones must all be balanced for optimal health. Putting hormones in a healthy body enhances their effect and safety.

Reproductive hormones include estrogen, estriol, progesterone, and testosterone.

We provide discounts for military, education (teachers and students), first responder, and medical personnel. We recognize the incredible healing potential of these therapies and partner with Advance Care to provide interest-free medical financing. Our services are also HSA-eligible.

Insurance does not yet cover Dr. Kaveh's advanced approach to individualized BHRT. Clarus Health provides patients a superbill to assist in obtaining reimbursement from your insurance. Contact us to find which codes apply to you.

Patients who experience symptom relief with the SGB often experience 2-3 months of improvement. Some patients will experience much longer symptom relief (over a year). There is no one-size-fits-all approach. We individualize therapies to last as long as possible for each patient. Some strategies to maximize the benefit of an SGB include cognitive behavioral therapy, IV Ketamine, and IV NAD+.

We provide discounts for military, education (teachers and students), first responder, and medical personnel. We recognize the incredible healing potential of these therapies and partner with Advance Care to provide interest-free medical financing. Our services are also HSA-eligible.

Insurance does not yet cover the latest applications of the Stellate Ganglion Block. Clarus Health provides patients a superbill to assist in obtaining reimbursement from your insurance. Contact us to find which codes apply to you.

Many patients will benefit from NAD+ boosters, especially before and after major stressors. Some common stressful events include surgery, athletic events, or psychologically taxing experiences. Some conditions, like chronic fatigue and Parkinson's, benefit from regular NAD+ infusions. Clarus Health aims to use the fewest number of interventions for the greatest therapeutic benefit.

Our BR+ NAD infusions take 2-5 hours depending on the dose. This duration is because our product is over 99.5% pure NAD+. Since there is no "dissociative" component to NAD, you can read a book or watch a show on your laptop during your infusion.

NR infusions typically last less than 1 hour. Like NAD+ there is no "dissociative" component to the NR infusion.

We provide discounts for military, education (teachers and students), first responder, and medical personnel. We recognize the incredible healing potential of these therapies and partner with Advance Care to provide interest-free medical financing. Our services are also HSA-eligible.

Insurance does not yet cover NR or NAD+ because it is used off-label for these indications. Clarus Health provides patients a superbill to assist in obtaining reimbursement from your insurance. Contact us to find which codes apply to you.

Because Spravato is FDA-approved, most major insurance plans cover it - including Medicare, Medi-Cal, and commercial insurers - for patients who meet the criteria for treatment-resistant depression or major depressive disorder with suicidal ideation. At our San Francisco clinic we accept Aetna, United Healthcare, Cigna, Medicare, Anthem Blue Cross Blue Shield, and Blue Cross Blue Shield of California for Spravato.

Every plan requires prior authorization, which generally takes anywhere from a few days to a few weeks. We verify your benefits and handle that paperwork before your first session, so you receive a clear out-of-pocket estimate before committing to treatment. This is the main practical advantage of Spravato over IV ketamine, which is used off-label and rarely covered.

Spravato is approved for adults with treatment-resistant depression, generally meaning depression that has not responded adequately to at least two antidepressants, and for adults with major depressive disorder with suicidal ideation. As of 2025 it is also the first and only monotherapy approved for treatment-resistant depression, so eligible patients no longer need a daily oral antidepressant alongside it. Most insurers require documentation of those earlier medication trials as part of prior authorization.

It is not appropriate for everyone. Patients with uncontrolled high blood pressure, aneurysmal vascular disease, a history of psychosis, or active substance use disorder are generally not candidates. Our San Francisco intake evaluation, conducted by our physician team, identifies any contraindications before treatment begins.

Most patients experience a temporary dissociative state — a sense of floating, detachment from surroundings, altered perception of time, or dreamlike thinking. It usually begins within minutes and fades well within the two-hour monitoring window you spend in a private room at our San Francisco office.

You will not be able to drive afterward and should arrange a ride home. Many patients use the hours following a session for quiet reflection or journaling, which our integration therapy team can guide.

Not quite. Spravato is esketamine, one half of the ketamine molecule, delivered as a nasal spray. The ketamine used in IV infusions is the full compound. Both act on NMDA receptors and trigger neuroplasticity.

The practical differences matter more than the chemistry. Spravato is FDA-approved and usually insurance-covered, but its approval is limited to depression. IV ketamine is used off-label and rarely covered, but it can address anxiety, PTSD, chronic pain, and addiction, with faster onset and higher bioavailability. Our San Francisco clinic offers both and recommends based on your diagnosis, coverage, and goals — we cover the tradeoffs in detail in our guide to IV versus nasal ketamine.

In a head-to-head trial against one of the most common alternatives for treatment-resistant depression, Spravato produced significantly higher remission rates at eight weeks, with benefits sustained through 32 weeks.

That said, the best option depends on your full clinical picture. At our San Francisco clinic we also offer stellate ganglion block, genomic testing to guide medication selection, and hormone optimization, since untreated hormonal or metabolic issues frequently sustain depression that looks purely psychiatric.

Treatment follows a tapering schedule rather than a fixed number. The induction phase is twice weekly for roughly the first four weeks, then once weekly, then every one to two weeks for maintenance as your response stabilizes.

Staying on maintenance matters: patients who reach remission and continue treatment see a substantially lower risk of relapse than those who stop. Your San Francisco provider reassesses at every visit and adjusts your protocol accordingly.

The most common are dissociation, dizziness, nausea, temporarily elevated blood pressure, sedation, and headache. Nearly all resolve within the two-hour monitoring period, and your clinical provider manages them in real time.

Spravato carries a boxed warning for sedation, dissociation, and abuse potential, which is precisely why it must be administered in a certified clinic under supervision rather than taken at home. Across nearly six years of real-world use, its safety profile has remained consistent with what clinical trials predicted.

Spravato is a Schedule III controlled substance and carries a boxed warning for abuse and misuse, so the concern is a fair one. The risk is managed structurally rather than left to chance.

The medication is never dispensed for you to take home. You self-administer it in the clinic under direct supervision and are monitored for two hours afterward. These requirements exist under the FDA's REMS program specifically to prevent misuse, and every session at our San Francisco clinic is supervised by a licensed clinical provider.